Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728805 · ClinicalTrials.gov registry record · Phase 3
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
A Phase 3 study, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 3
- Development phase
- 372
- Enrollment target
NCT01728805 is a Phase 3 study that has completed, run by Kyowa Kirin. The registered enrollment target is 372 participants.
The verdict
NCT01728805, a Phase 3 study, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 372 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
Interventions
- DRUG Vorinostat
- BIOLOGICAL KW-0761
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2012-11 |
| Est. Completion | 2021-02-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01728805
The ClinicalTrials.gov registry entry for NCT01728805 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT01728805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01728805 about?
NCT01728805 is a clinical study titled "Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL". The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
What is the current status of trial NCT01728805?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 372 participants. The study started on 2012-11. Estimated completion is 2021-02-17.
What interventions are being tested in trial NCT01728805?
The interventions under investigation include: Vorinostat (DRUG), KW-0761 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01728805?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.